Skip to main content

Advertisement

Table 6 Comparative investigations of the possibility to substitute paclitaxel with other drugs

From: Therapeutic strategies in epithelial ovarian cancer

Study Treatment arms FIGO stage n PFS (m) OS(m) p
SCOTROC-1   III-IV     0.71
  Carboplatin (AUC5)+Paclitaxel (175 mg/mq)   539 14.8 N.A  
  Carboplatin (AUC5)+Docetaxel (75 mg/mq)   538 15.0 N.A  
MITO-2   IC-IV     N.S.
  Carboplatin (AUC5) + Paclitaxel (175 mg/mq)   410 16.8 53.2  
  Carboplatin (AUC5) + Liposomal doxorubicin (30 mg/mq)   410 19.0 61.6  
  1. N.A.: not accessed
  2. N.S.: not significant